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Lung  transplantation  was  pioneered  more  than  50  years  ago
by  James  Hardy  and  introduced  into  clinical  practice  in
1986,  by  Joel  Cooper  and  soon  after,  by  Alexander  Patterson.
Since  then,  and  through  constant  improvements,  lung  trans-
plantation  was  offered  to  over  30  000  patients  worldwide,
establishing  itself  as  the  standard  therapy  for  end-stage  pul-
monary  disease.  Lung  transplantation  has  allowed  patients
with  chronic  and  terminal  respiratory  failure,  a  signiﬁcant
improvement  in  their  quality  of  life  and  prolonged  survival.
Patients  that  are  candidates  to  receive  a  new  lung,  normally
have  a  life  expectancy  that  is  inferior  to  18  months,  and  the
mean  survival  after  single  or  double  lung  transplantation  is,
at  the  present,  well  over  60%  at  3  years.1
Lung  transplantation  is,  without  question,  a  very  complex
surgical  intervention.  Not  only  due  to  operative  technical
challenges,  but  also  due  to  the  fact  that  chronic  respira-
tory  failure  produces  a  dramatic  impact  on  global  physical
condition  of  the  transplant  candidates,  inducing  an  extreme
frailty,  and  putting  them  at  the  highest  surgical  risk.  This  is
the  reason  why  great  care  must  be  given  on  the  selection  of
candidates,  in  order  to  minimize  peri-operative  risk.
But  not  only  surgery  is  demanding  --  pre  operative  selec-
tion  and  optimization  --  be  it  for  the  nutrition  status,  the
physiotherapy,  the  sterilization  of  infections  and  the  general
care,  at  large,  that  must  all  be  pondered.  Post-operative
care  is,  equally,  challenging,  as  these  patients  combine
the  need  for  respiratory  optimization,  cardiac  support,
renal  function  tuning,  and  the  most  strict  ﬂuid  balance.
Immediate  post-operative  results  do  translate  this  need  for
expertise,  compensating  well  for  complexity,  with  an  early
mortality  that  stays,  for  us,  well  below  10%.
Ischaemic  and  reperfusion  lesions,  early  after  trans-
plantation,  and  infection  versus  rejection,  latter,  will
threaten  every  post-operative  period,  requiring  constant
surveillance,  requesting  expertise  and  imposing  frequent
adjustments.  Later  on,  chronic  rejection,  leading  to
silent  obliterating  bronchiolitis,  will  compromise  functional
capacity  and  ultimately  affect  late  survival,  this  in  con-
junction  with  the  risk  for  neoplasms,  as  for  any  chronically
immune-depressed  patients.
Lung  transplantation  needs  a  multidisciplinary  team
that  constantly  interacts  --  that  is  to  say,  needs  a  true
interdisciplinary  team,  comprising  surgeons  --  thoracic
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naesthesiologists,  infectious  diseases  specialists,  nutrition
nd  psychology  specialists,  perfusion  technicians,  nurses,
hysiotherapists,  image  specialists  and  all  other  suppor-
ing  staff.  Different  from  other  surgical  endeavours,  lung
ransplantation  is,  by  no  means,  a  one  man’s  show,  it  is
mperative  team  work!  This  team  requires  volume,  and  vol-
me  imposes  the  minimum  of  15--20  cases,  yearly  to  provide
nough  expertise.
Lung  transplantation  depends  on  suitable  candidates,
perated  within  what  is  called  the  optimal  ‘‘transplantation
indow’’,  but  also  depends  on  suitable  donors,  as  it  is  well
nown  that  the  lungs  are,  possibly,  the  most  sensitive  organs
o  preserve  and  keep  in  good  conditions  prior  to  transplant.
rom  all  identiﬁed  donors,  not  more  than  20%,  at  the  very
est,  will  be  suitable  for  lung  donation.  Several  strategies
o  increase  the  donor  pool  are  being  introduced  --  expand-
ng  criteria,  optimizing  donor’s  general  conditions  and,  more
ecently,  ex  vivo  perfusion  preservation,  non-beating  heart
onors  and  lobar  donation,  are  all  being  considered.  We
ave  practiced  all,  but  the  last  two,  and  the  ex  vivo  per-
usion  is  being  developed  for  introduction  into  our  practice
n  a  very  near  future.  One  thing  is  clear  to  all  transplant
pecialists  -- there  is  no  good  lung  transplantation  without
ptimized  donation,  this  being  one  area  that  needs  further
ocusing,  if  the  numbers  and  quality  of  transplantation  are
o  be  increased.
There  is  one  single  centre  performing  lung  transplan-
ation  in  Portugal,  our  centre.  This  allows  for  experience
oncentration,  though  being  negatively  considered  by  some
or  being  an  ‘‘orphan  centre’’.  For  the  ﬁrst  time  this  year,
nd  even  more  importantly  than  having  celebrated  the  lung
ransplant  number  100,  we  will  reach  the  magic  mark  of  20
ung  transplants  yearly,  not  far  from  our  estimated  national
eeds.  However,  this  number  is  arguable,  as  there  is  also  a
reat  discrepancy  for  lung  transplantation  ﬁgures  in  Europe,
rom  0.2  per  million  to  6  per  million. .  .
At  the  moment,  30  patients  are  on  our  waiting  lung  trans-
lantation  list  and,  for  them,  the  mean  time  on  the  list  is,
resently,  250  days.  Our  donor  acceptance  rate  is  18%,  a  ﬁg-
re  that  is  similar  to  other  international  centres,  but  that
opefully  will  improve  with  the  introduction  of  the  ex  vivo
reservation  techniques.  Having  said  that  the  yearly  needs
lsevier España, S.L.U. All rights reserved.
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n  Portugal  may  well  be  slightly  over  20  cases,  we  are  con-
inced  that,  more  offer  would  create  more  need,  however,
ne  limitation  would  be  the  size  of  the  pool  of  donors  in
ortugal,  that  is  already  being  utilized  in  full  extent  by  our
ung  programme.
So  far,  106  lung  transplantations  were  performed  at  our
entre,  this  representing  an  acceptance  rate  of  24%  and  a
efusal  rate  of  57%,  these  due  mainly  to  the  presence  of
ormal  transplantation  contra-indications.
From  those  transplanted,  45%  were  double  lungs,  mainly
or  infected  lung  diseases,  as  cystic  ﬁbrosis  or  bronchiec-
asis,  or  for  concomitant  pulmonary  hypertension.  The
ajority  of  transplants  (53%)  were  performed  due  to
arenchymal  disorders,  as  lung  ﬁbrosis.  The  other  diagno-
is  for  lung  transplantation  was  COPD  in  22%,  Cystic  Fibrosis
CF)  in  16%  and  non-CF  bronchiectasis  in  the  remaining  9%.
Outcomes  are  remarkedly  good,  once  the  learning  curve
as  overcome,  showing  now  great  stability  of  results:  At
his  moment  in  time,  64%  of  all  patients  that  underwent  a
ung  transplant  at  our  centre  are  still  alive,  with  a  median
urvival  of  55.5  months,  the  longest  survival  in  the  series
eaching  12  years.
Lung  transplantation  survival  curves  (Kaplan--Meier)  show
 3-month  survival  of  83.5%  (95%  CI  75--90),  a  12  months  sur-
ival  of  71.3%  (95%  CI  61--80)  and  same  values  at  24,  36  and
0  months  are,  respectively,  67%  (95%  CI  56--76);  56.8%  (95%
I  44--68)  and  48.5%  (95%  CI  33--62).  These  ﬁgures  compare,
f  I  may  say,  even  favourably  with  those  regularly  published
y  the  voluntary  registry  of  the  International  Society  of
eart  &  Lung  Transplantation.2EDITORIAL
Lung  transplantation  is  an  expensive  activity,  providing
ood,  though  very  expensive  returns.  The  direct  cost  for  any
ransplanted  patient  is,  for  us,  79  316.07  D with  the  price
f  one  QALY  levelling  at  approximately  three  times  the  nor-
al  accepted  for  other  considered  as  cost-effective  medical
nterventions.3 However,  the  very  favourable  impacts  on  the
uality  of  life  of  many  of  those  patients,  among  whom,  I
ight  recall  the  youngsters  with  cystic  ﬁbrosis,  a  cohort  for
hich  our  transplantation  mortality  nearly  approaches  zero,
akes  the  team  value  their  daily  demanding  work,  at  the
ervice  of  our  national  centre,  and  say,  like  Einstein  --  ‘‘not
verything  that  can  be  measured  counts  and  not  everything
hat  counts  can  be  measured’’.
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